AKT1 and cancer: Capivasertib was previously shown to inhibit all three isoforms of AKT (AKT1, AKT2 and AKT3) in enzyme assays and reduce phosphorylation of its downstream substrates P70S6K or PRAS40 and in vitro growth of a subset of various cancer cell lines and xenografts [36,37].